#USA #Dublin #Jazz Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Reports Robust Financial Results for Q1 2026

Overview

On May 5, 2026, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the first quarter of 2026 (1Q26), demonstrating a remarkable revenue increase of 19% year-over-year (YoY), totaling $1.1 billion. This growth reflects the company's strong commercial execution across several franchises and continuing progress in its pipeline developments.

Renee Gala, the president and CEO of Jazz Pharmaceuticals, expressed optimism regarding the company's performance, stating, "Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026." Gala emphasized the sustained demand for Xywav, robust launches of new products such as Modeyso™ and Zepzelca® for various cancer types, and the steady growth of Epidiolex.

Key Highlights

1. Revenue Growth: The total revenue for 1Q26 was $1.1 billion, marking a 19% increase from the previous year.
2. Earnings Per Share: The company generated GAAP and non-GAAP adjusted earnings per share (EPS) of $4.43 and $6.34, respectively, with $408 million generated from operations during the quarter.
3. Product Performance:
- Xywav: Reported net sales increased by 18% YoY, generating $408 million, supported by approximately 425 new patients added this quarter.
- Epidiolex: Sales rose by 15% YoY to $250 million, driven by strong demand and an agreement with Nippon Zoki for Japan commercialization pending regulatory approval.
- Zanidatamab (Ziihera): Recorded net sales of $13 million in the biliary tract cancer segment.
- Modeyso (dordaviprone): Generated net sales of $41 million and is on track with ongoing clinical trials.
- Zepzelca (lurbinectedin): Experienced a 60% revenue increase YoY to $101 million, benefiting from its combination with atezolizumab.

Business Updates and Future Outlook

The results also shed light on the rapid advancements in Jazz Pharmaceuticals' pipeline. Notably, the FDA has granted Priority Review for the Supplemental Biologics License Application (sBLA) of zanidatamab in treating advanced gastroesophageal adenocarcinoma (GEA), with a target action date of August 25, 2026. The HERIZON-GEA-01 trial presented phase 3 results that position zanidatamab as a pivotal HER2-targeting treatment, reinforcing confidence in its potential success.

Looking ahead, Jazz Pharmaceuticals has reaffirmed its revenue and expense guidance for 2026, forecasting total revenues between $4.25 billion and $4.5 billion. This projection is bolstered by the anticipated launch of zanidatamab and momentum in its oncology portfolio.

Financial Performance Analysis

Revenue Breakdown

• - Total Revenue: $1,068.9 million (2026) vs. $897.8 million (2025)
• - Product Sales: Key drivers included strong performances from Xywav, Epidiolex, and oncology therapies.

Cost Management

Despite a rise in overall operating expenses, Jazz Pharmaceuticals maintained a healthy gross margin. The cost of product sales amounted to $134.1 million, reflecting a gross margin of 87.5%.

Cash Flow and Balance Sheet

As of March 31, 2026, Jazz reported cash, cash equivalents, and investments totaling $2.9 billion. The outstanding long-term debt stood at $5.4 billion, with a revolving credit capacity of $885 million. The available cash flow underscores Jazz's commitment to operational excellence and strategic decision-making moving forward.

Conclusion

Jazz Pharmaceuticals' first-quarter performance showcases not only impressive financial results but also a formidable pipeline expanding towards novel therapeutic solutions. As it continues to navigate the dynamic pharmaceutical landscape, Jazz remains focused on delivering value for its shareholders and transformative therapies for patients in need. This momentum positions the company as a critical player in the biopharmaceutical sector, particularly within the realm of oncology and rare diseases. Investors and stakeholders can anticipate exciting developments as Jazz Pharmaceuticals progresses through 2026 and beyond.